Page 120 - THE EVOLUTION OF EARLY ARTHRITIS AND CARDIOVASCULAR RISK Samina A. Turk
P. 120

CHAPTER 6
Table 1. Demographics and outcomes at baseline and after four weeks of anti-rheumatic treatment
 Demographics
Baseline
After 4 weeks
 Age 48.5
Gender (females) 70
Symptom duration (months) 7.0
RF positive 82
ACPA positive 86
RF or ACPA positive 89
RA disease
DAS44 3.5
VAS44 61.4
SJC44 8.0
TJC44 8.0
ESR 20.5
CRP 7.2
HAQ 1.0
CV risk components
History of CV events 7
Current smoking 26
Statin use 5
Antihypertensive use 16
BMI 26.1
Syst RR‡ 130.8
Dia RR‡ 80.5
TC† 5.0
HDL† 1.4
LDL† 3.2
Trigly† 1.3
TC:HDL ratio† 3.9
CV risk scores
Dutch SCORE linear risk score ∆ 11.0
Dutch SCORE low risk score∆ 43
Dutch SCORE medium risk score∆ 25
Dutch SCORE high risk score∆ 29
Heart SCORE linear risk score∆ 0.0
Heart SCORE low risk score∆ 90
Heart SCORE medium risk score∆ 4
Heart SCORE high risk score∆ 3
(12.4)
(67.3%)
[3.0-21.0]
(78.8%)
(82.7%)
(86%)
(3.3) 1.6
(27.2) 22.3
[3.0-13.0] 2.0
[4.0-16.0] 1.5
[9.0-32.8] 7.0
[3.8-25.0] 2.0
[0.5-1.6] 0.3
(6.7%) 7
(25.0%) 25
(4.8%) 5
(15.4%) 16
(5.3) 26.3
(22.5) 127.8
(11.5) 78.4
(0.9) 5.7
(0.4) 1.9
(0.8) 3.3
(0.6) 1.5
(1.3) 3.2
[3.5-23.5] 10.0
(44.3%) 46
(25.8%) 20
(29.9%) 31
[0.0-1.5] 0.0
(92.8%) 94
(4.1%) 1
(3.1%) 2
(0.9)*
(22.6)*
[0.0-3.3]*
[1.5-5.0]*
[5.0-12.0]*
[0.9-4.1]*
[0.0-0.6]*
(6.7%)
(24%)
(4.8%)
(15.4%)
(5.4)
(17.7)
(10.0)*
(1.1)*
(0.5)*
(0.9)*
(0.8)*
(1.0)*
[3.0-22.0]*
(47.4%)
(20.6%)
(32.0%)
[0.0-1.5]*
(96.9%)
(1.0%)
(2.1%)
                                    118
   118   119   120   121   122